Martingale Asset Management L P purchased a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) in the second quarter, Holdings Channel.com reports. The firm purchased 13,387 shares of the company’s stock, valued at approximately $103,000.
Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences in the 2nd quarter valued at about $84,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at about $101,000. Bridgefront Capital LLC purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at about $103,000. Point72 Hong Kong Ltd lifted its holdings in shares of Kodiak Sciences by 893.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 14,557 shares of the company’s stock valued at $112,000 after purchasing an additional 13,092 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Kodiak Sciences by 55.6% in the 1st quarter. MetLife Investment Management LLC now owns 18,141 shares of the company’s stock valued at $140,000 after purchasing an additional 6,480 shares during the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts have recently weighed in on the company. Citigroup reduced their target price on Kodiak Sciences from $8.00 to $6.00 in a report on Thursday, November 10th. Truist Financial boosted their price target on Kodiak Sciences from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. The Goldman Sachs Group dropped their price target on Kodiak Sciences from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Thursday, November 10th. Chardan Capital dropped their price target on Kodiak Sciences from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Finally, Morgan Stanley dropped their price target on Kodiak Sciences from $12.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Monday, November 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.11.
Kodiak Sciences Trading Down 1.6 %
Kodiak Sciences (NASDAQ:KOD – Get Rating) last released its earnings results on Wednesday, November 9th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.82) by $0.35. Equities analysts forecast that Kodiak Sciences Inc. will post -6.68 earnings per share for the current fiscal year.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.